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Abstract

The purpose of this study was to examine the effects of a six-month testosterone
supplementation on bone mineral density (BMD) in males ages 19-62. Recruiting
potential subject through a local clinic, five subjects were eligible for participation in the
study. A pre-supplementation DEXA scan was used to measure BMD of the lumbar
spine and hip. A post-supplementation DEXA was done after six months of
supplementation; the same sites were scanned. Of the initial five subjects, three subjects
completed the study. All subjects showed an increase in serum testosterone levels (∆=
+537 ng/dL). After the supplementation subject one showed an increase in BMD for
both hip locations, and his total BMD from all three scans improved. Subject two also
showed increases in BMD in both hips and total BMD. Despite overall increase in BMD,
subject one and subject two both showed a decrease in BMD in the lumbar spine region.
Subject three showed a slight decrease in cumulative BMD; however, subject three
lacked an initial scan for the lumbar spine region, which could have contributed to the
final changes in BMD. Post supplementation, all three subjects observed augmented
energy levels. Overall, testosterone supplementation was shown to help maintain or
improve BMD in two out of three subjects. Continued addition of subjects will allow for
statistical evaluation of data in the future.

Keywords: testosterone, bone mineral density, supplementation, lumbar spine, hip
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Chapter One

The U.S Department of Health reports state that in 2004 and 2006 ten million
Americans were diagnosed with osteoporosis; two million were males (U.S. Department
of Health and Human Services, 2004; U.S. Department of Health and Human Services,
2006; Pande et al., 2006). However, this number grossly underestimates the number of
Americans living with osteoporosis (U.S. Department of Health and Human Services,
2004); however, this number merely scratches the surface of the millions of Americans
currently living with low bone mineral density (BMD). Osteopenia is diagnosed when a
person is found to have BMD 1 standard deviation (SD) below that of a normal, healthy
adult; osteoporosis is diagnosed when a person is found to have bone mineral density 2.5
SD below the bone mineral density of a normal, healthy adult. Hence, having decreased
BMD is not synonymous with having osteoporosis. However, just as with osteoporosis,
decreased BMD has associated health concerns. Decreased BMD causes bones to be
more susceptible to fractures. Annually, osteoporosis causes 1.5 million bone fractures in
America with associated costs between 12- 17 billion dollars (U.S. Department of Health
and Human Services, 2004; Farley & Blalock, 2009; Pande et al., 2006). Not only are the
economic impacts of low BMD fractures substantial, but the physical repercussions of
fractures alarming. People suffer bone fractures from low BMD are associated with
increased mortality rates, increased morbidity and decreased quality of life (U.S.
Department of Health and Human Services, 2004; Vondracek & Hansen, 2004). For
example, three months following an osteoporotic fracture, mortality risks among people
who experience fractures increases 2.8 to 4 fold (U.S. Department of Health and Human
Services, 2004). Though low BMD is easily diagnosed and can be successfully treated if
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caught early, the lack of visible symptoms cause low BMD to often go unnoticed until a
patient’s BMD has decreased to being classified as osteoporosis.
Within the past several decades substantial advancements have been made in
research pertaining to causes, consequences and cures of low BMD, particularly in
patients with osteoporosis (Farley & Blalock, 2009). As the body’s regulation of bone
density becomes better understood, physicians and researchers have been able to
introduce multiple methods to stop bone loss and prevent low BMD fractures. Initially,
physicians and researchers strongly promote the use of preventative measures for
everyone who is at risk for low BMD fractures such as the elderly, sedentary individuals
and post menopausal women (U.S. Department of Health and Human Service, 2004;
Sweet, Sweet, JerMiah, & Galazaka, 2009). Examples of preventative measures include
exercise, proper nutrition and methods of fall prevention such as railings and non-slip
surfaces (U.S. Department of Health and Human Service, 2004; Sweet et al., 2009).
Research also strongly advocates the benefits calcium and vitamin D provide for general
bone health, specifically BMD. Medical treatment options for low BMD in both sexes
include hormone replacement therapy, bisphosphonates, and other medications (Farley &
Blalock, 2009; Nieschlag et al., 2004). Hormone replacement therapy, which includes
supplementation of androgens, such as testosterone and estrogens, has been a longstanding method for osteoporosis treatment in females and has recently become a popular
method for treating osteoporosis in males (Nieschlag et al., 2004). However, as new
hormone treatment methods develop and new understandings of hormones’ varied effects
within the body are discovered, hormonal therapy requires continued research.
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Osteoporosis has been long identified as a “woman’s disease”; therefore, research
pertaining to osteoporosis and even low BMD in males drastically lags behind research
on osteoporosis and low BMD in women. Thus, the two million males with osteoporosis
are limited in treatment options. Today, testosterone supplementation is a common
treatment method for low BMD in males. However, the majority of current research
available includes populations of males 70 years of age and above (Anderson, Francis,
Peaston, & Wastell, 1997; Nayak, Roberts, & Greenspan, 2009; Spry et al., 2009; Synder
et al., 1999). To date, some studies have seen great benefits in using testosterone
supplementation as a treatment for low BMD (Anderson, Francis, & Faulkner, 1996;
Behre et al., 1997, Farley & Blalock, 2009; Wang et al.2006). However, several studies,
particularly studies done with a placebo group, challenge these findings (Snyder et al.,
1999; Tracz et al. 2006). Therefore, more information is needed to understand the effects
of testosterone supplementation in men with low BMD who are younger than 62 years of
age. Hence, the purpose of this study is to investigate the effect of testosterone
supplementation on males 19-62 with low BMD indicating osteopenia or osteoporosis.

TESTOSTERONE SUPPLEMENTATION AND BMD

4

Chapter Two
Low BMD
In 2004, the Surgeon General released data reporting that ten million Americans
are diagnosed with osteoporosis. The Surgeon General also specifies that of these ten
million Americans with osteoporosis, two million are males (2004). As discussed above,
osteoporosis is defined as bone mineral density (BMD) 2.5 SD below the mean and
osteopenia as BMD 1 SD below the mean of the average BMD of healthy adults
(Surgeon General, 2004). It is estimated that 2-6% of males in the United States are
living with osteoporosis with an additional 28-47% of males living with osteopenia
(Khosla, Amin, & Orwoll, 2008). Despite the fact that males only account for one-fifth
of diagnosed cases of osteoporosis, one-fourth of all hip fractures and half of all vertebral
fractures occur in males (Farley & Blalock, 2009). Fractures caused by low BMD not
only cost 12 billion dollars annually but also cause high rates of mortality and morbidity
among males who suffer from them (Surgeon General, 2004).
A study done by Pande et al. (2006) followed 200 males for two years: the sample
included and experimental group of 100 males with low BMD hip fractures and a control
group of 100 males without hip fractures. Researchers found a six to seven fold increase
in mortality rate among males greater than 50 years of age who had suffered an
osteoporotic hip fracture. In addition to increased mortality rates, researchers also saw an
increase in morbidity in males who suffered a hip fracture. Two years following the
initial fracture, 70 of the 100 males never returned home. Of those 70 males, 58 males
died while the remaining 12 were placed in assisted living homes. In correlation with
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these findings a study performed by Trombetti et al. (2002) calculated a decrease of 5.8
years in life expectancy after a man experienced a hip fracture.
Though the consequences of osteoporosis are well known, physiological factors
initiating low BMD are not well defined. Currently, the causes of low BMD in males can
be divided into two categories: idiopathic causes and secondary causes (Vondracek &
Hansen, 2004). Idiopathic causes are primary causes and are diagnosed if low BMD
appears without depreciated androgen levels, specifically testosterone levels within
normal levels (eugonadal). In such a case, low BMD may occur due to the presence of
one or more factors such as: age, genetics, low body mass index and low calcium and
vitamin D intake or decreased absorption (Vondracek & Hansen, 2004). Secondary
causes are diagnosed when low BMD occurs due to lifestyle changes or changes in
hormone levels. Secondary causes include abnormally low levels of testosterone
(hypogonadism), alcoholism, sedentary lifestyle, hyperthyroidism and aging (Vondracek
& Hansen, 2004).

Androgens and Bone Health
When osteoclast (bone reabsorbers) activity outweighs osteoblast (bone builders)
activity, the bone is left porous and brittle (Vanderschueren et al., 2005). Androgens play
a role in osteoblast and osteoclast balance through two pathways: decreasing osteoblast
apoptosis and decreasing osteoclast reabsorption of bone. Androgens, specifically
estrogen, play a role in osteoblast and osteoclast balance through the production of
RANKL, a physiological agent known to lift osteoclast off the surface of the bone
(Hadley & Levine, 2007). With osteoclast removed from the surface, osteoblasts have
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the opportunity to lay down bone without reabsorption leading to an overall increase in
bone density. Consequently, the decrease in the production of estrogen, which occurs in
postmenopausal females, will lead to a drastic change in BMD. In males, testosterone
produced in the testes will be transformed into estrogen by the enzyme aromatase at the
target tissue, in this instance the surface of the bone. Therefore, testosterone in males
plays a similar physiological role in the conservation of BMD as estrogen plays in
females. However, due to the complexity of testosterone’s role in BMD maintenance,
testosterone supplementation alone in males does not yield the same results as estrogen
supplementation in females.
Vanderschueren et al. supplemented castrated mice with androgens and observed
that the addition of testosterone and estrogen helped protect the mice from bone loss
(2005). Androgen concentrations, such as testosterone and estrogen, decrease over the
lifespan. Testosterone and estrogen levels are lower in older adults, and low levels of
testosterone and estrogen are related to an increased osteoblast apoptosis and lower
BMD. Due to similarities in mice and human skeletons, if a stable or increasing BMD is
seen within mice supplemented with androgens after initial low androgen concentrations,
supplementing humans with androgens should elicit similar effects (Vanderscheruen et
al., 2005). Thus, androgens should play a significant role in maintaining BMD and could
be used to treat patients suffering from low BMD.
Hypogonadism. Males suffering from hypogonadism have decreased
testosterone production (testosterone levels are measured in ng/dL). Low levels of
testosterone can stem from one of two causes; a decrease in testosterone released from
the gonads, or a failure of the central nervous system to produce Luteinizing Hormone
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(LH) and Follicle Stimulating Hormone (FSH) (Vorvick, 2010). Secreted by the anterior
pituitary, LH and FSH signal the gonads to produce androgens, testosterone in the male.
Hence, decreased production or released of LH or FSH would lead to a decreased output
of testosterone from the gonads. Regardless of its initial cause, hypogonadism can lead
to multiple problems in the body such as: decreased libido, loss of hair or whole-body
weakness (Vorvick, 2010). Hypogonadism is linked to an increased chance of
developing low BMD and osteoporosis due to androgens’ effect on bone health.
Due to the physiological diversity among humans, each body needs and produces
an individualized amount of testosterone. Testing for testosterone levels requires a
simple blood test. On average, a male’s testosterone levels will be between 300-1000
ng/dL. A male suffering from hypogonadism will have a testosterone concentration
below 220-250 ng/dL (Fairman, 2000) or below the adjusted value for males their same
age and current fitness level. Often, physicians use his/her own discrepancy when
diagnosing a man with hypogonadism.

Treatment of low BMD
To date, there are four main medical treatments for low BMD in both males and
females: calcitonin, raloxifene, hormone therapy, and bisphosphonate (Farley & Blalock,
2009). Bisphosphonates are considered to be the first-line treatment, followed secondly
by calcitonin and raloxifene and lastly by hormone therapy. Though the study done by
Farley and Blalock encourages medical treatment of low BMD, specifically osteoporosis,
with bisphosphonates, it is important to note that the study included a male and female
population. Due to differences in the roles hormones play in the female body and
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hormonal changes that occur as the female ages, males and females respond to hormonal
therapy differently. Farley and Blalock addressed the benefits associated with all
treatment types; specifically how hormonal replacement therapy has shown great success
in treatment of males with low BMD due to hypogonadsim (2009).
Effects of Testosterone Supplementation. As discussed above, decreased
testosterone levels are not only associated with aging, but also can occur as a result of
secondary causes such as hypogonadism, hypothyroidism, alcoholism, or sedentary
lifestyle (Francis, 1999). Regardless of initial causes of low testosterone, low levels in
males may lead to erectile dysfunction, altered mood, decreased erythrocytosis, decreased
fertility or low BMD (Rhoden & Morgentaler, 2004). Low testosterone levels can be
reversed with testosterone supplementation. Side effects of testosterone supplementation
include: potential improvements on cardiovascular disease risks, increased erythrocytosis,
sleep apnea, infertility and gynecomastia (Rhoden & Morgentaler, 2004).
Anderson, Francis, & Faulkner (1996) examined the effects of testosterone on
BMD as well as cardiovascular risk factors such as cholesterol levels, triglyceride levels,
diastolic blood pressure, hematocrit composition and plasma viscosity. Twenty-three
eugonadal males with osteoporosis were followed for a six-month period during which
time they received intramuscular injections every other week. Cardiovascular disease
risk factors were examined every three months of the intervention. BMD was measured
pre and post treatment. Subjects saw a significant increase in lumbar spine BMD from
the initial measure of 0.799 ± 0.019 g/cm3 to the final measure of 0.839 ± 0.018 g/cm3, no
significant (p=0.05) changes were found in the neck, femoral trochanter, or hip. The
effect of testosterone on cardiovascular risk factors include the following: decrease in
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total cholesterol by 0.3 mmol/L, decrease in triglyceride levels by 15-20%, decrease in
blood pressure by 5 mmHg in both systolic and diastolic measures, increase in hematocrit
due to an anticipated erythrocytosis and an increase in plasma viscosity due to increased
levels of hematocrit. No adverse effects on cardiovascular disease were seen from the
supplementation of testosterone (Anderson, Francis, & Faulkner, 1996).

Testosterone Supplementation and BMD
Studies with Hypogondal Males. BMD in hypogonadal males can be improved
through the use of testosterone supplementation (Wang et al., 2004; Farley & Blalock,
2009; Behre et al., 1997). A two-year study by Wang et al., (2004), followed BMD of
163 hypogonadal males ages 19-64. The men took daily testosterone supplements via Tgel applied daily at multiple sites on the body. The only side effect reported was mild
skin irritation at application site. At the end of the initial six-months, there was an
average 2% increase in lumbar spine BMD accompanied by an increase in testosterone
from hypogonadal to normal levels. At the end of the two-year intervention both hip and
spine showed improvements in BMD. In addition subjects reported an increased sexual
function, elevated mood, improved body composition and restoration of testosterone
levels (Wang et al., 2004).
Behre et al., (1997) completed a longitudinal study examining the long-term
effects testosterone supplementation has on 72 males ages 19-74 suffering from both
idiopathic and secondary causes of osteoporosis. Mean age of subjects was 35 years.
The study lasted up to 16 years. Subjects were treated with intramuscular injections
(n=52), transdermal patches (n=11) and testosterone pellets (n=2). In all three methods,
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the greatest increase in testosterone levels occurred in the first year of supplementation.
Subjects all reached normal testosterone levels within three years of supplementation.
Researchers concluded that after restoring testosterone levels, BMD remained within
normal range as related to age regardless of supplement method used. No serious side
effects or reasons to quit treatment were observed (Beher et al., 1997).
Placebo Studies. A study by Snyder et al. (1999) looked at the differences
between males supplemented with testosterone versus males supplemented with a
placebo pill. The study involved 108 hypogonadal males over the age of 65. Prior to
treatment each group had a mean age of 73. Researchers randomly divided 108 males
into placebo or testosterone groups, so that no significant differences in age or physiology
existed between the two groups. Testosterone supplementation or administration of a
placebo was done through orally ingested pills taken daily for a total of 36 months. Of
the 108 males that began the study 96 males completed the study. The study showed the
placebo group had an initial serum testosterone level of 369 ± 75 ng/dL and a BMD in L1
and L2 of 1.214 ± 0.132 g/cm3, and the testosterone group had an initial serum
testosterone level of 367 ± 79 ng/dL and a BMD in L1 and L2 of 1.184 ± 0.142 g/cm3.
After the six-months of supplementation, the testosterone group’s serum and free
testosterone levels rose to 625 ± 249 ng/dL. The group’s testosterone levels remained
stable throughout the rest of the trial. No change in serum and free testosterone was seen
in the placebo group. BMD increased within both groups: a 0.6% increase of BMD in
placebo group and a 0.8% BMD increase in testosterone group. Post three years of
supplementation no significant differences in BMD were found between the two groups.
However, there was a significant increase in BMD between the placebo and testosterone
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groups as related to the initial serum testosterone (IST) levels: 0.9% increase seen in IST
of 400 ng/dL; 3.4% increase seen in IST of 300 ng/dL, and 5.9% increase seen in IST of
200 ng/dL (Synder et al., 1999).
Tracz et al. (2006) compiled a meta-analysis of eight studies on testosterone
supplements versus placebo supplements. Variation between studies included: mean
subjects ages ranging from 42 to 73 years, initial serum testosterone levels ranging from
291ng/dL to 457 ng/dL, sample from 16 subjects to 108 subjects, and intervention
durations from three to thirty-six months of treatment. Analysis of studies revealed a 4%
increase in lumbar spine BMD using intramuscular testosterone injections but no
significant improvement in neck or femoral densities. No significant increases in BMD
were reported at any region for placebo and transdermal testosterone groups (Tracz et al.,
2006).
Studies with Eugonadal Males. The question remains, can low BMD in
eugonadal males be improved through the use of testosterone therapy? A study
conducted by Anderson, Francis, Peaston, & Wastell (1997) tested the effects of
testosterone intramuscular injections on eugonadal males suffering from osteoporosis.
Subjects did not supplement with calcium or vitamin D (Anderson et al., 1997). A
sample of 21 males ages 23-73 completed the study with injections of testosterone every
other week. At the end of six months, subjects had an average 5% increase in lumbar
spine BMD with no significant changes in BMD of the neck, trochanter of femur, or hip
(Anderson et al., 1997). Two men failed to complete the study due to non-related health
complications (Anderson et al., 1997). Complaints from the remaining males consisted
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of stiffness and soreness at the injection site, but no other adverse side effects were
reported (Anderson et al., 1997)
Conclusion
Some studies show that testosterone supplementation has beneficial effects on the
treatment of low BMD in hypogonadal and eugonadal males (Anderson, Francis, &
Faulkner, 1996; Behre et al., 1997, Farley & Blalck, 2009; Wang et al.2006). However,
some literature suggests that testosterone supplementation has no significant effect on
BMD (Synder et al., 1999; Tracz et al., 2006). Thus, this study will investigate the
effects of a six-month testosterone supplementation regiment on BMD in osteopenic and
osteoporotic males ages 19-62.
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Chapter 3
Purpose
The purpose of this study is to investigate the effect of six-months of testosterone
supplementation on younger men ages 19-62 with low BMD indicating osteopenia or
osteoporosis.

Sample
All subjects included in the study were males ages 19-62. To qualify, all subjects
had a BMD T-score measure of -0.9 or less (diagnosis for osteopenia) in at least one site
measured. Measurements were taken from both the lumbar spine and dual femur regions
via DEXA scan (GE Lunar Prodigy, Diegem Belgium). Subjects were referred to the
study through a local health clinic, Forward Health Solutions. Dr. Rebecca Boyd, D.O.
recommended the study to all males with low testosterone levels. Males were not
receiving testosterone supplementation for more than three weeks prior to initial DEXA
scan.

Procedures
Before consenting to participate, subjects were reminded of the beneficial and
adverse effects of testosterone supplementation before the initial DEXA scan. Beneficial
and adverse effects of supplementation were also thoroughly discussed with subjects by
Dr. Rebecca Boyd prior to referral to the study. Prior to inclusion in the study, all
subjects completed a health history questionnaire (HHQ) and a full physical examination.
Eligible subjects were then provided with a written consent form outlining the purpose,
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benefits and risks. All consent forms were completed prior to initial DEXA scan.
Researchers also gave a verbal explanation of the study prior to initial DEXA scan. The
adverse side effects of testosterone that were discussed with subjects included:
erythrocytosis, gynocamastia, decreased fertility and fluid retention. Dr. Rebecca Boyd
supervised and managed all testosterone administration and adjusted testosterone
supplementation as needed.
Subjects contacted Kara Palmer to schedule initial DEXA scans. The DEXA scan
measured BMD in the lumbar spine and femoral trochanter. After the initial DEXA scan,
subjects with a BMD below -0.9 SD below the mean at one or more sites were asked to
participate in the study. Subjects who consented to participate in the study were given a
verbal reminder of participant expectations, benefits and possible adverse effects. Serum
testosterone levels were obtained from Dr. Rebecca Boyd upon subject entrance into the
study.
Subjects with health complications or a health history deemed unsuitable for
participation in the study were excluded. Exclusion criteria included failure to complete
the full six-month supplementation regiment or a subject choosing not to continue
participation. The University of Southern Mississippi IRB Board approved all
procedures.

Variables
Dependent Variables. In this study, the dependent variable measured was the
BMD of both the lumbar spine and femoral trochanter. All BMD measurements were
operationalized via DEXA scan. DEXA scans are non-invasive, include minimal
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radiation exposure and are frequently performed at the Laboratory of Applied
Physiology. Completion of a DEXA scan takes an approximated 6 minutes. Subjects
were asked to complete two DEXA scans, one at the beginning of the study and one after
six-months of supplementation
Subjects were given results of DEXA scan, a $350 value each, at no cost. The
study then compared the initial and final DEXA scans and determined the changes in
BMD in the spine and femoral trochanter. The overall BMD change was then used to
determine the impact of testosterone supplementation on BMD at each site measured and
overall BMD.
Independent Variables. In this study the independent variable was testosterone
supplementation. Testosterone supplementation may be administered one of three ways:
crème, injections, or pellets. Supplementation methods were individualized to each
subject and tailored to each subject’s personal needs.
Control Variables. Since evidence links environmental factors to the
development of low BMD, control variables include weekly physical activity, calcium
intake, vitamin D supplementation, weight lifting activities, age, occupation, and diet
with special interest in dairy intake (Sweet et al., 2009). All control variables will be
accounted for through a brief questionnaire the subject will complete prior to initial
DEXA scan. However, until sample size increases to where statistical analysis is
possible, control variables were not represented here.
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Final Disposition of Data
Throughout the duration of the study, all data collected was assembled and filed
in the office of Dr. Joseph Boyd at the University of Southern Mississippi. All data is to
be kept confidential and findings are reported in such a way that protects the subjects’
identity. For publication purposes, all participants are referred to by a pseudonym. All
data will remain on file for three years following completion of study.
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Chapter 4
Of the original five subjects that began the study, three completed the final sixmonth scan. Of the two that were excluded from the study, one discontinued use of
testosterone supplementation and the other failed to comply with the regulations of the
study. Demographic information about the three subjects that completed the study is
provided below (see Table 1).
Table 1
Demographic Analysis
Age (yrs)
Height (in)
Weight (lb)
Race
Caucasian
African American
T Levels (ng/dL)
Initial
Final
∆

48 ± 3.5
71 ± 2
196 ± 30
2
1
322 ± 175
855 ± 238
537

Due to a sample of three (n=3), statistical evaluation of data is not feasible at this
time. In this presentation of data, the results are presented as individual case studies
specific to each subject. The difference in BMD in all three locations scanned and the
overall change in BMD will be featured. As researchers continue to gather data, a
desired population size of n=8 should be accomplished in the future and the current data
revisited for statistical evaluation.
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Subject 1:
As shown in Table 2, subject one increased serum testosterone levels by +695
ng/dL reaching a total of 862 ng/dL from the original 167 ng/dL (see table 2). Along
with an increase in serum testosterone levels, the subject’s final DEXA scan showed an
increase in total BMD in both the left and right hip (∆= +0.022 g/cm3, ∆= +0.059 g/cm3)
but a decrease in BMD in the lumbar spine (∆= -0.012 g/cm3) (see Table 3). In the
lumbar spine, greatest increase was seen at L1 (∆= +0.042 g/cm3) and the greatest
decrease at L3 (∆= -0.094 g/cm3) (see Figure 2). In the left hip, the greatest increase in
BMD was seen in the shaft (∆= + 0.024g/cm3) and greatest decrease in the wards (∆=
-0.01 g/cm3) (Figure 3). In the right hip, the most substantial increase was seen in the
shaft (∆= +0.074 g/cm3) and the greatest decrease in the ward (∆= -0.052 g/cm3) (see
Figure 4). Overall, subject one had the greatest BMD decrease in L3 and the greatest
BMD increase in shaft of the right hip. Total initial BMD was 3.669 g/cm3 and final
BMD was 3.768 g/cm3. Therefore, after a 6-month supplementation with testosterone,
subject 1 saw an overall positive BMD difference of 0.069 g/cm3 (see Table 3).

Table 2
Subject 1: Demographics
Age
Height
Weight
Ethnicity
Days b/t scan
Initial T Level
Final T Level
Supp. Method
Dosage
Ethnicity

51 yrs
73 in
230 lbs
African American
181 days
167 ng/dl
862 ng/dl
Injections
200 mg day
African American
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Figure 1
Subject 1: Compared Totals

BMD (g/cm3)

2
1.5
1
Initial
0.5

Final

0
L1‐L4

L‐Total

R‐Total

Scan Site

Figure 2
Subject 1: Lumbar Spine
BMD (g/cm3)

2
1.5
1

Vetebral BMD
Initial

0.5

Vetebral BMD
Final

0

Scan Site
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Figure 3
Subject 1: L Hip
BMD (g/cm3)

1.4
1.2
1
0.8
0.6
0.4
0.2
0

Left Hip BMD
Initlal
Left Hip BMD
Final

Scan Site

1.4
1.2
1
0.8
0.6
0.4
0.2
0
R‐Total

R‐Shaft

R‐Troch

R‐Wards

Right Hip BMD
Initial
R‐Neck

BMD

(g/cm3)

Figure 4
Subject 1: R Hip

Right Hip BMD
Final

Scan Site

Table 3
Subject 1: Totals
Initial
(g/cm )
T score
1.632
3.4
1.052
-0.3
1.015
-0.6
3.699
3

L1-L4
L-Hip
R-Hip
Totals

Final
(g/cm )
T score
1.62
3.3
1.074
-0.2
1.074
-0.4
3.768
3

∆
3

(g/cm )
-0.012
+0.022
+0.059
+0.069

T score
-0.1
+0.1
+0.2
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Subject 2:
Over the course of the six-month testosterone supplementation, subject two saw
an increase in serum testosterone levels increased from 497 ng/dL to 1093 ng/dL. (∆=
+596 ng/dL) (see Table 4). In addition to increases in testosterone levels, the final scan
revealed an increase in both the left and right hip (∆= +0.009 g/cm3, ∆= 0.012 g/cm3) (see
Table 5). However, the BMD in the lumbar spine decreased (∆= -0.012 g/cm3) after sixmonths of supplementation (see Table 5). Within the lumbar region, the greatest increase
in BMD occurred in L2 (∆= +0.048 g/cm3) and the largest decrease in BMD occurred in
L4 (∆= -0.089 g/cm3) (see Figure 6). In the left hip the largest increase in BMD occurred
in the L-Troch (∆= +0.014 g/cm3) and the only decrease in the L-Wards (∆= -0.005
g/cm3) (see Figure 7). Unique to the right hip, only increases in BMD were seen (see
Figure 8). In the right hip the largest increase was in the R-neck (∆= +0.015 g/cm3) (see
Figure 8). Therefore, after six-months of testosterone supplementation, subject two saw
an increase in total BMD of +0.009 g/cm3 (see Table 5).
Table 4
Subject 2: Demographic Analysis
Age
Height
Weight
Ethnicity
Days b/t scan
Initial T Level
Final T Level
Supp Method
Dosage

44 yrs
70 in
195 lbs
Caucasian
223 days
497 ng/dL
1093 ng/dL
Topical Gel
(200 mg/ml)
2 clicks (.5 ml) once
daily
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Figure 5
Subject 2: Compared Totals

BMD (g/cm3)

1.2
1
0.8
0.6
0.4

Initial

0.2

Final

0
Lumbar

L‐Hip

R‐Hip

Scan Site

Figure 6
Subject 2: Lumbar Spine
1.1
1.05
Vetebral BMD
Initial

1
0.95

Scan Site

L1‐L4

L4

L3

L2

0.9
L1

BMD (g/cm3)

1.15

Vetebral BMD
Final
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BMD (g/cm3)

Figure 7
Subject 2: LHip
1.2
1
0.8
0.6
0.4
0.2
0

L Hip BMD
Initial
L Hip BMD
Final

Scan Site

BMD (g/cm3)

Figure 8
Subject 2: R Hip
1.2
1
0.8
0.6
0.4
0.2
0

Initial
Final

Scan Site

Table 5
Subject 2: Totals
Initial
3

L1-L4
L-Hip
R-Hip
Totals

(g/cm )
1.045
0.824
0.802
2.671

Final
T score
-1.5
-1.9
-2.1

3

(g/cm )
1.033
0.833
0.814
2.68

∆
T score
-1.6
-1.9
-2.0

3

(g/cm )
-0.012
0.009
0.012
0.009

T score
-0.1
0.0
+0.1
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Subject 3:
Subject three saw an increase of serum testosterone from 290 ng/dL to 610 ng/dL
(∆= +320 ng/dL) (see Table 6). This change in testosterone was the smallest increase in
testosterone seen among all subjects. Due to a systems failure, the data for the initial
lumbar scan for subject three was not usable. Data from the final scan is still presented
but not included in the final BMD calculations. After the final scan, subject three’s right
hip increased in BMD (∆= +0.002 g/cm3), but his left hip decreased (∆= -0.039 g/cm3)
(see Table 7). In the right hip, the largest increase in BMD (∆= +0.011 g/cm3) was found
at the R-troch (see Figure 12). No change was seen at the R-wards. At the left hip, no
increase in BMD was found, but a decrease (∆= -0.039 g/cm3) was seen at the L-Troch
(see Figure 11). Overall, subject three saw the only decrease in total BMD of -0.037
g/cm3 (see Table 7).
Table 6
Subject 3: Demographic Analysis
Age
Height
Weight
Ethnicity
Days b/t scan
Initial T Level
Final T Level
Supp. Method
Dosage

49 yrs
71 in
165 lbs
Caucasian
188 days
290 ng/dL
610 ng/dL
Injections every two
weeks
.75 mL
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Figure 9
Subject 3: Totals
1.25
1.2
1.15
1.1
1.05
1
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Lumbar
Spine

L‐Hip
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Scan Site

BMD (g/cm3)

Figure 10
Subject 3: Lumbar Spine
1.4
1.2
1
0.8
0.6
0.4
0.2
0
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Final

Scan Site
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BMD (g/cm3)

Figure 11
Subject 3: L Hip
1.4
1.2
1
0.8
0.6
0.4
0.2
0

Initial
Final

Scan Site

BMD (g/cm3)

Figure 12
Subject 3: RHip
1.4
1.2
1
0.8
0.6
0.4
0.2
0

Initial
Final

Scan Site

Table 7
Subject 3: Totals
Initial
(g/cm )
T score
na
1.088
-0.1
1.03
-0.5
2.118
3

L1-L4
L-Hip
R-Hip
Totals

Final
(g/cm )
T score
1.213
-0.1
1.049
-0.4
1.032
-0.5
2.081
3

∆
3

(g/cm )
1.213
-0.039
0.002
-0.037

T score
-0.3
0.0
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Chapter 5
The purpose of this study was to examine the effects of a six-month testosterone
supplementation on BMD in males 19-62. Addressing this issue and considering the
relationship between testosterone and bone density, we hypothesized that an increase in
testosterone in males with initially low testosterone concentrations may increase BMD.
Sites measured included the lumbar spine region and both hips. Measurements were
taken within the first three weeks of testosterone supplementation and after six months of
consistent supplementation. Results concluded that a six-month testosterone
supplementation increased total BMD in subject one and two. After a six-month
intervention subject one and two showed an increase in BMD in both hip regions;
however, they also showed a decrease of BMD in the lumbar spine region. In subject
three, a decrease in total BMD was shown. This decrease could be attributed to a systems
failure resulting in the loss of the lumbar spine, which could have altered final BMD
totals.
In addition to just looking at final BMD, researchers should examine the changes
in BMD in relation to the difference in serum testosterone levels. Subject one saw the
greatest increase in serum testosterone. He also showed the greatest increase in total
BMD. Subject three had the smallest increase in testosterone levels; his was the only
decrease in total BMD seen. Hence when more data becomes available, researchers need
to not only compare supplementation time with improvements, but also compare changes
in BMD with changes in serum testosterone levels.
Lastly, during the final DEXA scan researchers asked subjects of any other
changes seen throughout the supplementation period. Subjects unanimously reported an
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increase in energy levels and decrease in daily fatigue. None of the subjects reported any
adverse side effects with supplementation.
Due to demographics of the surrounding area, sample size remained small.
Subjects had to travel to The University of Southern Mississippi campus to receive both
scans which proved challenging and often delayed final scans to longer than the desired
180 days. Two participants were discontinued from the program, one due to failure to
comply with the terms of the study and one stopped receiving supplementation prior to
the six-month scan. Continued research in this study would require a larger population,
potentially partnerships with multiple hormonal replacement clinics and more consistent
completion of final DEXA scans. Researchers will continue to gather data from new
subjects referred to the study.
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